Reports Q2 revenue $114.4M, consensus $100.2M. “We continue to make strong progress against our strategic priorities, putting Travere on a trajectory for both near- and long-term growth. This quarter marked our strongest commercial performance to date, with increased momentum for FILSPARI resulting in significant growth in a dynamic IgAN market,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics (TVTX). “Looking ahead, we are well positioned to continue advancing FILSPARI toward becoming a foundational treatment. In parallel, we are preparing for a potential approval in FSGS, where FILSPARI would become the first FDA-approved therapy -bringing a long-awaited option to patients and further extending our impact in rare kidney diseases. We also look forward to our upcoming August PDUFA date for REMS modification, which could result in important label updates that support broader access to FILSPARI. Additionally, we are making steady progress toward restarting enrollment in our pivotal study of pegtibatinase, moving us closer to potentially delivering the first disease-modifying therapy for people living with classical HCU.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Buy Rating for Travere Therapeutics: Strong Market Position and Growth Potential with Filspari and FSGS Expansion
- Buy Rating on Travere Therapeutics: Undervaluation Amidst IgAN and FSGS Opportunities
- Travere Therapeutics asumed with a Buy at H.C. Wainwright
- Buy Rating for Travere Therapeutics: Anticipated FDA Approval and Strategic Developments Signal Significant Upside Potential
- Citi trims Travere target, opens ‘upside 90-day catalyst watch’